Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2015-01-07 Regulatory Filings
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates that the filing is pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and includes a press release as an exhibit. The document is short (2639 characters) and primarily serves to furnish information under Regulation FD, with no substantive financial statements or detailed financial analysis included. It does not contain an annual or quarterly report, audit report, earnings release, or other detailed financial disclosures. The document is essentially an announcement of a press release rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2015-01-07 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 7, 2015, by Galectin Therapeutics Inc. The key content is the posting of a corporate presentation on the company's website, which is attached as Exhibit 99.1. The report states that the information is furnished under Item 7.01 Regulation FD Disclosure and specifically mentions a corporate presentation. There are no financial statements or detailed financial data included in the text, only a reference to the presentation. The document length is 2812 characters, which is relatively short and consistent with an announcement or furnishing of a presentation rather than a full report. According to the classification rules, a corporate presentation attached or referenced in an 8-K under Regulation FD is best classified as an Investor Presentation (IP).
2015-01-07 English
PRIMARY DOCUMENT
Director's Dealing
2014-12-17 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details an amended and restated employment agreement with the company's Chief Operating Officer, including terms of employment and compensation. This fits the category of announcements related to changes in senior management or board members. The document does not contain financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. It is not a proxy statement, earnings release, or other categories. Therefore, the best classification is Board/Management Information (MANG). The document length is 3567 characters, which is consistent with a typical 8-K filing for management changes.
2014-12-12 English
PRIMARY DOCUMENT
Director's Dealing
2014-11-19 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text indicates that the company posted a corporate presentation regarding its Phase 1 clinical trial and attached it as Exhibit 99.1. The document itself is short (2297 characters) and primarily announces the posting of a corporate presentation rather than containing detailed financial data or the presentation itself. According to the 'Menu vs Meal' rule, this is an announcement of a report (the corporate presentation) rather than the report itself. Therefore, the appropriate classification is 'Investor Presentation' (IP) because the document announces and attaches a corporate presentation for investors.
2014-11-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.